news
Researchers identify drug target for treatment of malabsorption in babies
Scientists have found a hormone peptide called YY that presents a promising drug target for malabsorption in babies.
List view / Grid view
Research & Development
news
Assay that mimics SARS-CoV-2 infection could test potential COVID-19 drugs
Scientists have developed a new assay that uses nanoparticles to mimic how SARS-CoV-2 infects a cell, which could be used to screen for drugs that treat COVID-19.
news
Treg cells could be used in immunotherapy to treat multiple sclerosis, study shows
Researchers have discovered how Tregs can reduce spinal cord injury caused by diseases like multiple sclerosis (MS).
news
Researchers discover druggable pocket on SARS-CoV-2 Spike protein
A pocket in the SARS-CoV-2 Spike protein has been discovered by researchers, who say it could be a drug target for COVID-19.
news
Novel pseudo-virion probes to study SARS-CoV-2 viral entry
The non-infectious quantum dot probes are designed to enable researchers to safely study interactions between the SARS-CoV-2 Spike (S) protein and human cells.
article
The next generation of cancer immunotherapies: re-exploring the IL-2 pathway
In this article, Dr Bruce Dezube explains why new cancer immunotherapy drugs that utilise the IL-2 pathway with lower side effects could offer more benefits compared to high-dose IL-2 treatment.
news
Drug target to combat three coronavirus diseases identified by researchers
Researchers studying the PLpro binding site of three coronaviruses, including SARS-CoV-2, say the BL2 loop could be targeted by antiviral drugs.
news
Novel antiviral drug candidate blocks SARS-CoV-2 reproduction in cells
In human cells, a drug candidate called PF-00835231 has demonstrated success at blocking the reproduction of SARS-CoV-2.
article
Understanding the limits of synthetic biology through the origins of SARS-CoV-2
Conspiracy theories about COVID-19 have been spreading since the early days of the outbreak. But how do we know whether a biological entity is artificially made or has occurred naturally? Marc Baiget Francesch explores the capabilities of current scientific approaches in terms of virus engineering and how this applies to…
news
Novel molecule restores lost connections in spinal cords and brains of mice
Researchers have developed a molecule that can restore lost connections in the spinal cords and brains of mice with cerebellar ataxia, Alzheimer's disease and spinal cord injury.
news
Researchers target previously “undruggable” enzyme to treat Duchenne muscular dystrophy in cells
By targeting a previously undiscovered allosteric site on a DMD-associated enzyme, researchers found muscle cell conditions improved.
article
Exploring the intra-protein non-covalent interactions in the S1 domain of the SARS-CoV-2 S1 Spike protein
The Spike (S) protein is a promising drug target in the quest to develop vaccines and antivirals for SARS-CoV-2 to treat and prevent COVID-19. Intra-protein interaction energy landscape mapping efforts have recently identified key interactions that may be crucial for the S protein’s ability to bind to receptor proteins on…
article
Powering forward – Genomics England’s COVID-19 response
Genomics England has launched a next-generation genomic research platform that will play a key role in the response to COVID-19. It is hoped this research environment will transform how genomic data is made usable for global biopharma and academic scientists, providing world‑class patient data security, while enabling the flexibility required…
article
Under the microscope: Supporting the COVID-19 response with NGS
Responding efficiently to urgent situations is of utmost importance in times of crisis. Dr Suvarna Gandlur, Associate Director of Takara Bio’s next-generation sequencing (NGS) portfolio, discusses how the company is contributing to the COVID-19 effort and supporting the scientific community.
article
Expert view: Measuring protein interactions in blood – not as trivial as it sounds
In the continuing battle against COVID-19, researchers now must identify the best candidates for vaccines and convalescent serum therapies against the virus.